# 119-hr-1082: Shandra Eisenga Human Cell and Tissue Product Safety Act

119-hr-1082, Shandra Eisenga Human Cell and Tissue Product Safety Act, is a 119th Congress bill sponsored by Rep. Moolenaar, John R. [R-MI-2] (R-MI); status passed_house; PRIA reads it as touching household money (as of 2026-09-03).

- Canonical: https://policyrisk.com/legislation/119-hr-1082
- As of: 2026-09-03
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-hr-1082
- Congress: 119
- Title: Shandra Eisenga Human Cell and Tissue Product Safety Act
- Status: passed_house
- Introduced: 2025-02-06
- Sponsor: Rep. Moolenaar, John R. [R-MI-2] (R-MI)
- Cosponsors: 1
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-09-03

## Summary

**This bill would strengthen safety and oversight of human cell and tissue products** by clarifying key definitions, boosting education for clinicians and donors, and adding civil penalties for regulatory violations. - Patients and donors would see clearer public information on donation, available screening tests, and Tissue Reference Group timelines through FDA-published materials and annual reports on registered establishments, inspections since 2019, inquiries, and average response times. - Clinicians and transplant teams would get targeted educational materials, workshops, and interactive sessions to improve how they approach donation and obtain timely, accurate recommendations from the Tissue Reference Group. - HCTP establishments and other regulated entities would face civil penalties of up to $20,000 per violation and $20,000 per day after notice, plus the retail value of the products, with a $10.0 million cap per proceeding; the bill also creates a public docket and a workshop to inform updated recommendations on regulation, with a summary and recommendations due by September 30, 2026.

## Cosponsors (1)

- Rep. Dingell, Debbie [D-MI-6] (D-MI), 2025-02-06T00:00:00.000Z

## Provisions PRIA read

- FDA would update tissue product rules: benefit, low. The FDA would open a public docket within 60 days to get comments on modernizing tissue product rules. Within 1 year, and then yearly for 3 years, the FDA would post key metrics on its website. These include registered establishments since 2019, inspection counts with blood-bank comparisons, Tissue…
- Big fines for tissue product violations: cost, high. If enacted, businesses that break FDA tissue product rules would face large fines. The bill would set $20,000 for each violation. After written notice, it would add $20,000 for each day the violation continues. It would also charge the retail value of the products involved. Total penalties in one c…

## Related bills

- 119-hr-3151: SHIPS for America Act of 2025
- 119-hr-9237: Take Care of America’s Veterans Act
- 119-hr-2725: Affordable Housing Credit Improvement Act of 2025
- 119-hr-3654: TERRA Act
- 119-hr-137: TCJA Permanency Act
- 119-hr-6766: Essential Caregivers Act of 2025

## Sources
- [119-hr-1082 on Congress.gov](https://www.congress.gov/bill/119th-congress/house-bill/1082)

## Related
- [119-hr-3151: SHIPS for America Act of 2025](https://policyrisk.com/legislation/119-hr-3151)
- [119-hr-9237: Take Care of America’s Veterans Act](https://policyrisk.com/legislation/119-hr-9237)
- [119-hr-2725: Affordable Housing Credit Improvement Act of 2025](https://policyrisk.com/legislation/119-hr-2725)
- [119-hr-3654: TERRA Act](https://policyrisk.com/legislation/119-hr-3654)
- [119-hr-137: TCJA Permanency Act](https://policyrisk.com/legislation/119-hr-137)
- [119-hr-6766: Essential Caregivers Act of 2025](https://policyrisk.com/legislation/119-hr-6766)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-hr-1082 (as of 2026-09-03).